Formulation, optimisation andin-vitro,in-vivoevaluation of surfactant stabilised nanosuspension ofGinkgo biloba / Saba Aslam, Nazish Jahan, Khalil-Ur-Rehman , Shaukat Ali
Abstract The purpose of this research work was to formulate the stable nanosuspension of Ginkgo biloba to increase its oral bioavailability. To achieve this goal, initially nanosuspensions of G. biloba were prepared with six different stabilisers. Afterwards, other formulation conditions were optimised with response surface methodology. Stabiliser screening study selected sodium lauryl sulphate as stabiliser to formulate the nanosuspension of G. biloba by antisolvent precipitation method. Under suggested optimal conditions of software, nanosuspension of G. biloba with mean particle size 139.5 nm, polydispersity index 0.258 and zeta potential 58.7 mV was prepared. Atomic force microscopy showed sheet like shape and very well distribution of G. biloba nanoparticles with approximate height of 15–30nm. Optimised nanosuspension of G. biloba demonstrated greater in-vitro dissolution and more plasma concentration of quercetin in G. biloba nanosuspension administrated rats in comparison to coarse suspension. Moreover, cytotoxicity study revealed no toxic effects of formulated nanosuspension.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Journal of microencapsulation - 36(2019), 6, Seite 576-590 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aslam, Saba [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Cytotoxicity |
|---|
| Umfang: |
1 Online-Ressource (15 p) |
|---|
| doi: |
10.1080/02652048.2019.1662123 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011203676 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011203676 | ||
| 003 | DE-627 | ||
| 005 | 20231109210045.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230714s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/02652048.2019.1662123 |2 doi | |
| 035 | |a (DE-627)KFL011203676 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/02652048.2019.1662123 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Aslam, Saba |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Formulation, optimisation andin-vitro,in-vivoevaluation of surfactant stabilised nanosuspension ofGinkgo biloba |c Saba Aslam, Nazish Jahan, Khalil-Ur-Rehman , Shaukat Ali |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (15 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The purpose of this research work was to formulate the stable nanosuspension of Ginkgo biloba to increase its oral bioavailability. To achieve this goal, initially nanosuspensions of G. biloba were prepared with six different stabilisers. Afterwards, other formulation conditions were optimised with response surface methodology. Stabiliser screening study selected sodium lauryl sulphate as stabiliser to formulate the nanosuspension of G. biloba by antisolvent precipitation method. Under suggested optimal conditions of software, nanosuspension of G. biloba with mean particle size 139.5 nm, polydispersity index 0.258 and zeta potential 58.7 mV was prepared. Atomic force microscopy showed sheet like shape and very well distribution of G. biloba nanoparticles with approximate height of 15–30nm. Optimised nanosuspension of G. biloba demonstrated greater in-vitro dissolution and more plasma concentration of quercetin in G. biloba nanosuspension administrated rats in comparison to coarse suspension. Moreover, cytotoxicity study revealed no toxic effects of formulated nanosuspension | ||
| 653 | |a Nanoprecipitation | ||
| 653 | |a Ginkgo biloba | ||
| 653 | |a response surface methodology | ||
| 653 | |a dissolution study | ||
| 653 | |a pharmacokinetics | ||
| 653 | |a cytotoxicity | ||
| 700 | 1 | |a Jahan, Nazish |e verfasserin |4 aut | |
| 700 | 1 | |a , Khalil-Ur-Rehman, Khalil-Ur-Rehman |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Shaukat |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of microencapsulation |d Abingdon : Taylor & Francis Group, 1984 |g 36(2019), 6, Seite 576-590 |h Online-Ressource |w (DE-627)KFL000005967 |w (DE-600)1491079-2 |w (DE-576)079719244 |x 1464-5246 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2019 |g number:6 |g pages:576-590 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/02652048.2019.1662123 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_02 | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2019 |e 6 |h 576-590 | ||